G1 Therapeutics Inc (NASDAQ:GTHX) VP Jennifer K. Moses sold 750 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $22.99, for a total value of $17,242.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

G1 Therapeutics Inc (NASDAQ GTHX) traded down $0.02 during trading hours on Thursday, reaching $21.51. The company had a trading volume of 2,099 shares, compared to its average volume of 73,331. G1 Therapeutics Inc has a one year low of $12.04 and a one year high of $28.67.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.55) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.01. equities analysts forecast that G1 Therapeutics Inc will post -2.72 earnings per share for the current fiscal year.

Several analysts recently weighed in on the company. Zacks Investment Research lowered G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. JPMorgan Chase & Co. increased their price target on G1 Therapeutics to $30.00 in a report on Monday. BidaskClub lowered G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 3rd. BTIG Research assumed coverage on G1 Therapeutics in a report on Tuesday, December 19th. They set a “buy” rating and a $38.00 price target on the stock. Finally, Cowen restated a “buy” rating on shares of G1 Therapeutics in a report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $32.80.

Institutional investors have recently made changes to their positions in the business. American International Group Inc. bought a new position in G1 Therapeutics in the 3rd quarter valued at $130,000. Swiss National Bank bought a new position in G1 Therapeutics in the 4th quarter valued at $286,000. Hodges Capital Management Inc. bought a new position in G1 Therapeutics in the 4th quarter valued at $292,000. California State Teachers Retirement System bought a new position in G1 Therapeutics in the 3rd quarter valued at $319,000. Finally, Schwab Charles Investment Management Inc. bought a new position in G1 Therapeutics in the 3rd quarter valued at $364,000. 43.25% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This story was reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2018/02/08/insider-selling-g1-therapeutics-inc-gthx-vp-sells-750-shares-of-stock.html.

About G1 Therapeutics

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Insider Buying and Selling by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.